Apollo Endosurgery, Inc. (APEN): Price and Financial Metrics

Apollo Endosurgery, Inc. (APEN): $3.65

0.00 (0.00%)

POWR Rating

Component Grades














  • Sentiment is the dimension where APEN ranks best; there it ranks ahead of 88.31% of US stocks.
  • APEN's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • APEN's current lowest rank is in the Momentum metric (where it is better than 16.1% of US stocks).

APEN Stock Summary

  • APEN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 173.78 -- higher than 85.92% of US-listed equities with positive expected earnings growth.
  • Revenue growth over the past 12 months for Apollo Endosurgery Inc comes in at 49.8%, a number that bests 81.46% of the US stocks we're tracking.
  • Apollo Endosurgery Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -26.86%, greater than the shareholder yield of only 14.65% of stocks in our set.
  • Stocks that are quantitatively similar to APEN, based on their financial statements, market capitalization, and price volatility, are SWI, ICHR, TWOU, TAOP, and AGE.
  • APEN's SEC filings can be seen here. And to visit Apollo Endosurgery Inc's official web site, go to www.apolloendo.com.

APEN Valuation Summary

  • APEN's price/sales ratio is 4.5; this is 18.42% higher than that of the median Healthcare stock.
  • APEN's price/sales ratio has moved down 122.6 over the prior 175 months.
  • Over the past 175 months, APEN's price/earnings ratio has gone down 6.9.

Below are key valuation metrics over time for APEN.

Stock Date P/S P/B P/E EV/EBIT
APEN 2021-08-31 4.5 93.6 -18.5 -34.2
APEN 2021-08-30 4.4 91.8 -18.2 -33.6
APEN 2021-08-27 4.3 89.5 -17.7 -32.8
APEN 2021-08-26 4.2 87.5 -17.3 -32.1
APEN 2021-08-25 4.1 84.8 -16.8 -31.3
APEN 2021-08-24 4.1 84.7 -16.8 -31.2

APEN Growth Metrics

    Its 4 year revenue growth rate is now at 5741.52%.
  • Its year over year net income to common stockholders growth rate is now at 51.39%.
  • Its 2 year net income to common stockholders growth rate is now at -28.21%.
APEN's revenue has moved up $23,379,000 over the prior 18 months.

The table below shows APEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 62.989 -14.454 -24.682
2021-09-30 59.678 -12.91 -17.782
2021-06-30 56.153 -13.949 -13.722
2021-03-31 45.187 -18.858 -16.956
2020-12-31 42.048 -20.812 -22.611
2020-09-30 41.177 -24.694 -26.302

APEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • APEN has a Quality Grade of D, ranking ahead of 22.64% of graded US stocks.
  • APEN's asset turnover comes in at 0.804 -- ranking 36th of 186 Medical Equipment stocks.
  • IDXG, BSGM, and ISR are the stocks whose asset turnover ratios are most correlated with APEN.

The table below shows APEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.804 0.554 -0.164
2021-06-30 0.733 0.549 -0.111
2021-03-31 0.619 0.534 -0.161
2020-12-31 0.590 0.529 -0.288
2020-09-30 0.584 0.507 -0.429
2020-06-30 0.555 0.488 -0.560

APEN Price Target

For more insight on analysts targets of APEN, see our APEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 1.38 (Strong Buy)

APEN Stock Price Chart Interactive Chart >

Price chart for APEN

APEN Price/Volume Stats

Current price $3.65 52-week high $10.39
Prev. close $3.65 52-week low $3.51
Day low $3.60 Volume 98,500
Day high $3.76 Avg. volume 163,808
50-day MA $4.42 Dividend yield N/A
200-day MA $6.68 Market Cap 146.91M

Apollo Endosurgery, Inc. (APEN) Company Bio

Apollo Endosurgery, Inc. focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system, a non-surgical alternative for the treatment of overweight and obese adults; and OverStitch, an endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through an Olympus dual-channel flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company is based in Austin, Texas.

APEN Latest News Stream

Event/Time News Detail
Loading, please wait...

APEN Latest Social Stream

Loading social stream, please wait...

View Full APEN Social Stream

Latest APEN News From Around the Web

Below are the latest news stories about Apollo Endosurgery Inc that investors may wish to consider to help them evaluate APEN as an investment opportunity.

Apollo Endosurgery up 17% after CFO adds shares

Apollo Endosurgery <> jumps after CFO Jeffrey G

Seeking Alpha | March 2, 2022

Apollo Endosurgery to Participate in the Cowen Healthcare Conference

AUSTIN, TX / ACCESSWIRE / March 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that Chas McKhann, CEO, and Jeff Black, CFO, will host investor meetings March 7-8, 2022 as part of the Cowen Healthcare Conference, taking place virtually.

Yahoo | March 2, 2022

Investing in Apollo Endosurgery (NASDAQ:APEN) three years ago would have delivered you a 58% gain

Apollo Endosurgery, Inc. ( NASDAQ:APEN ) shareholders might understandably be very concerned that the share price has...

Yahoo | February 25, 2022

Apollo Endosurgery, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 23, 2022

Apollo Endosurgery, Inc. (APEN) CEO Charles McKhann on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 22, 2022

Read More 'APEN' Stories Here

APEN Price Returns

1-mo -15.51%
3-mo -38.96%
6-mo -58.38%
1-year -55.70%
3-year 14.06%
5-year -55.05%
YTD -56.70%
2021 147.94%
2020 19.30%
2019 -17.39%
2018 -38.39%
2017 -53.95%

Continue Researching APEN

Want to see what other sources are saying about Apollo Endosurgery Inc's financials and stock price? Try the links below:

Apollo Endosurgery Inc (APEN) Stock Price | Nasdaq
Apollo Endosurgery Inc (APEN) Stock Quote, History and News - Yahoo Finance
Apollo Endosurgery Inc (APEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5053 seconds.